Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96

Inclusion Criteria: 1. Able to read and understand the informed consent document; must sign the informed consent; 2. Aged 18 to 75 years old , sex is not limited; 3. Pancreatic cancer or primary liver cancer,must have undergone radical resection; 4. Availability of at least 0.5 g tumor sample; 5. Receiving the first gp96 autologous immunotherapy within 8 weeks of postoperation; 6. Patients could not have received previous chemotherapy, radiation, or immunotherapy before 4 weeks of gp96 treatment； 7. ECOG ≤1；life expectancy of at least 12 weeks 8. Adequate bone marrow function including the absence of lymphopenia (ANC \> 1,500/ mm3; Hemoglobin \> 10g/dL ; platelet count \>100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase \[AST\], alanine amino transferase \[ALT\] \<2.5 times institutional upper limit of normals \[IULNs\] and bilirubin (total) \<1.5 times IULN), and adequate renal function (BUN and creatinine \<1.5 times IULNs); 9. Agree to Surgical indications of Heart \& lung and without the coagulation system disease; 10.Negative pregnancy test for female patients of childbearing potential; 11.Agree to use contraception or abstain from sexual activity from the time of consent through 3 month after the end of study drug administration. Exclusion Criteria: 1. Unable to get the informed consent ; 2. Patient not suitable for radical resection; 3. Patients with active liver disease； 4. Did not get enough tumor tissue ; 5. Progression prior to vaccination as determined by the Principal Investigator; 6. Rreceiving other anti-cancer therapy at the same time; 7. Patient with allergic constitution; 8. Unstable or severe intercurrent medical conditions; 9. Current diagnosis of Human Immunodeficiency Virus and Patients with active uncontrolled infection; 10. Patients with any systemic disease needed to be treated with immunosuppressant or Corticosteroids; 11. Any other cilical trials within 30 days pre-vaccination; 12. Female patients who are pregnant or breastfeeding.